Webcast - CHMP rekommenderar att Oncopeptides Pepaxti får ett fullt godkännande i EU
June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.
Conference call for investors, analysts, and media
Investors, financial analysts, and media are invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event will be hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor.
The webcast will be streamed via https://tv.streamfabriken.com/2022-pressconference.